<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72276">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02023242</url>
  </required_header>
  <id_info>
    <org_study_id>CP-12-001</org_study_id>
    <nct_id>NCT02023242</nct_id>
  </id_info>
  <brief_title>Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes</brief_title>
  <acronym>Hydrus V</acronym>
  <official_title>A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStent® for Lowering Intraocular Pressure in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares two implantable devices intended to lower the pressure inside
      the eye of glaucoma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-masked, randomized clinical trial comparing the
      Hydrus Microstent to two iStent implants for the reduction of intraocular pressure in phakic
      patients with a positive diagnosis of primary open angle glaucoma, pseudoexfoliative
      glaucoma, or pigmentary dispersion glaucoma.  Post-operative follow-up visits will be
      conducted at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular pressure at Month 12</measure>
    <time_frame>Twelve months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness endpoint for this study is IOP at 12 months following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication use at 12 and 24 months</measure>
    <time_frame>Months 12 and 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean medication use at 12 and 24 months post procedure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>Months 12 and 24</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety outcomes include complications and adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <condition>Pigmentary Glaucoma</condition>
  <arm_group>
    <arm_group_label>Hydrus Microstent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the Hydrus Microstent .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the iStent Trabecular Micro Bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Microstent</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>Hydrus Microstent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Trabecular Micro Bypass</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,
             or Pigmentary glaucoma (PG)

          -  A phakic lens with BCVA of 20/30 or better

        Exclusion Criteria:

          -  Forms of primary or secondary glaucoma not listed above

          -  Prior glaucoma surgery in the study eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Garcia Feijoo, Prof. Med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Madrid, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brett Trauthen</last_name>
    <phone>949/333-1315</phone>
    <email>btrauthen@ivantisinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Rhee, OD</last_name>
    <phone>949/333-1316</phone>
    <email>prhee@ivantisinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Contact Brett Trauthen at Ivantis</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>December 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Pseudoexfoliative glaucoma</keyword>
  <keyword>PXG</keyword>
  <keyword>Pigmentary glaucoma</keyword>
  <keyword>PG</keyword>
  <keyword>Hydrus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
